Haemonetics discusses lawsuit outcome

Haemonetics is dedicated to serving the blood collection industry, it has stated.

The company has received a favourable verdict in its lawsuit against Fenwal, in which it alleged the firm had infringed one of its patents.

Haemonetics has now been awarded $15.7 million (9.8 million pounds) in damages and Fenwal has been ordered to stop selling the Alyx consumable by December 1st 2010, as well as to pay the former ten per cent in royalties from sales of the product.

The lawsuit was necessary in order to protect the firm’s intellectual property, explained Haemonetics’ president and chief executive officer Brain Concannon.

He added the business is committed to working with customers to deliver blood management solutions to improve the standards of care and reduce costs.

“We are prepared to support customers through this transition period,” Mr Concannon concluded.

In April this year, Haemonetics acquired Neotric Technology, which is a privately held medical information management company.

During the first year of the takeover, it is expected the former will make neutral earnings.